GENZYME CORPORATION

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 35545
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 14548
 
 
 
C07D HETEROCYCLIC COMPOUNDS 9078
 
 
 
C07K PEPTIDES 8258
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 4155
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 3564
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 3465
 
 
 
A61F FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS 27113
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 2624
 
 
 
C08G MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS 2199

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0055,939 EXCIPIENTS FOR USE IN ADENO-ASSOCIATED VIRUS PHARMACEUTICAL FORMULATIONS AND PHARMACEUTICAL FORMULATIONS MADE THEREWITHMar 28, 17Mar 01, 18[A61K, C12N]
2017/0369,583 METHODS AND COMPOSITIONS FOR TREATING LUPUSMar 01, 17Dec 28, 17[A61K, C07K]
2017/0349,665 ANTI-CD52 ANTIBODIESJun 16, 17Dec 07, 17[C07K]
2017/0342,144 ENGINEERED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTSAug 07, 17Nov 30, 17[A61K, C07K]
2017/0334,888 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORSDec 30, 16Nov 23, 17[A61K, C07D]
2017/0326,203 Methods of Treating Autoimmune DiseasesAug 02, 17Nov 16, 17[A61K, C07K]
2017/0307,629 METHOD OF IDENTIFYING RISK FOR THYROID DISORDERMay 10, 17Oct 26, 17[A61K, G01N]
2017/0260,545 METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDSNov 15, 16Sep 14, 17[C12N]
2017/0247,664 COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATIONOct 06, 16Aug 31, 17[C12N]
2017/0233,464 Use of TGF-Beta Antagonists to Treat Infants at Risk of Developing Bronchopulmonary DysplasiaNov 28, 16Aug 17, 17[A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920318 β-actin and RPS21 promoters and uses thereofAug 01, 14Mar 20, 18[C07H, A61K, C12N, C07K]
9909101 Methods of perfusion culturing using a shake flask and microcarriersFeb 21, 14Mar 06, 18[C12N]
9895315 Aliphatic amine polymer salts for tabletingDec 14, 16Feb 20, 18[A61K]
9890394 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersApr 03, 09Feb 13, 18[A61K, C12N]
9834604 Inhibitors of T-cell activationJun 29, 12Dec 05, 17[C07K]
9815816 Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolineJul 22, 15Nov 14, 17[C07D]
9815892 Multimeric constructsJan 31, 14Nov 14, 17[A61K, C12P, C07K]
9790268 Fc containing polypeptides with altered glycosylation and reduced effector functionMar 11, 14Oct 17, 17[A61K, C12P, C07K]
9783604 Engineered anti-TGF-beta antibodies and antigen-binding fragmentsMar 11, 14Oct 10, 17[A61K, C12N, C07K]
9765144 Nucleic acids encoding anti-CXCR3 antibodiesSep 08, 14Sep 19, 17[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0326,172 Sachet Formulation for Amine PolymersAbandonedJan 26, 17Nov 16, 17[A61K]
2017/0281,593 Methods of Treating Fatty Liver DiseaseAbandonedDec 19, 16Oct 05, 17[A61K, C07D]
2017/0232,117 AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFORAbandonedOct 18, 16Aug 17, 17[A61K, C12N, C07K]
2016/0361,301 GLUCOSYLCERAMIDE SYNTHASE INHIBITORSAbandonedDec 09, 14Dec 15, 16[A61K]
2016/0287,549 NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASESAbandonedNov 21, 14Oct 06, 16[A61K]
2016/0256,534 METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORSAbandonedMar 25, 16Sep 08, 16[A61K, C12N]
2016/0130,249 Quinazoline Derivatives as VEGF InhibitorsAbandonedMay 22, 15May 12, 16[C07D]
2016/0120,842 AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASEAbandonedJan 13, 16May 05, 16[A61K]
2016/0083,694 COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATIONAbandonedMay 01, 15Mar 24, 16[C12N]
2016/0082,090 Use of Polysaccharides for Promotion of Enzymatic ActivityAbandonedSep 21, 15Mar 24, 16[A61K]
2016/0031,781 AGENT FOR IMPROVING TISSUE PENETRATIONAbandonedAug 03, 15Feb 04, 16[A61K, C07C]
2016/0024,233 SEQUESTRANTS OF ADVANCED GLYCATION END PRODUCT (AGE) PRECURSORSAbandonedMar 12, 14Jan 28, 16[C08F]
2016/0015,393 CONFINEMENT OF KIDNEY STONE FRAGMENTS DURING LITHOTRIPSYAbandonedFeb 25, 15Jan 21, 16[A61H, A61B]
2015/0321,996 AMIDE DENDRIMER COMPOSITIONSAbandonedMay 21, 15Nov 12, 15[C08G, C07C]
2015/0284,472 COMPOSITIONS AND METHODS FOR TREATING PROTEINOPATHIESAbandonedNov 04, 13Oct 08, 15[A61K, C07K]
2015/0283,170 COATED PHARMACEUTICAL COMPOSITIONSAbandonedApr 07, 14Oct 08, 15[A61K]
2015/0238,610 EXCIPIENTS FOR USE IN ADENO-ASSOCIATED VIRUS PHARMACEUTICAL FORMULATIONS, AND PHARMACEUTICAL FORMULATIONS MADE THEREWITHAbandonedOct 03, 14Aug 27, 15[A61K]
2015/0216,872 METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVESAbandonedNov 04, 14Aug 06, 15[A61K]
2015/0210,681 GLUCOSYLCERAMIDE SYNTHASE INHIBITORSAbandonedSep 10, 13Jul 30, 15[A61K, C07D]
2015/0196,586 POLYMERIC MOLECULAR RECEPTORS AS PHOSPHATE SEQUESTRANTSAbandonedFeb 06, 15Jul 16, 15[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.